A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, Christine Wilke A, Modemann F, Janning M, Serve H, Ganser A, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Heuser M.
Fiedler W, et al. Among authors: ganser a.
Br J Haematol. 2020 Aug;190(3):e169-e173. doi: 10.1111/bjh.16804. Epub 2020 Jun 9.
Br J Haematol. 2020.
PMID: 32515072
Free article.
Clinical Trial.
No abstract available.